Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jonathan A. Fletcher, M.D.

Co-Author

This page shows the publications co-authored by Jonathan Fletcher and James Griffin.
Connection Strength

0.164
  1. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood. 2010 May 27; 115(21):4206-16.
    View in: PubMed
    Score: 0.112
  2. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004 Oct 05; 101(40):14479-84.
    View in: PubMed
    Score: 0.019
  3. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003 Feb; 3(2):173-83.
    View in: PubMed
    Score: 0.017
  4. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001 Aug 16; 20(36):5054-8.
    View in: PubMed
    Score: 0.015
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.